Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.
Hospitalisation
ILD
IPF
Prognosis
Risk factors
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
16
08
2023
accepted:
30
10
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on hospitalisation patterns in ILD. The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for hospitalisations. Reasons for hospitalisation were classified as all cause, ILD-related and respiratory hospitalisations, and patients were analysed for frequency of hospitalisations, time to first non-elective hospitalisation, mortality and progression-free survival. Additionally, the risk for hospitalisation according to GAP index and ILD subtype was calculated by Cox proportional-hazard models as well as influencing factors on prediction of hospitalisation by logistic regression with forward selection. In total, 601 patients were included. 1210 hospitalisations were recorded during the 6 months prior to registry inclusion until the last study visit. 800 (66.1%) were ILD-related, 59.3% of admissions were registered in the first year after inclusion. Mortality was associated with all cause, ILD-related and respiratory-related hospitalisation. Risk factors for hospitalisation were advanced disease (GAP Index stages II and III) and CTD (connective tissue disease)-ILDs. All cause hospitalisations were associated with pulmonary hypertension (OR 2.53, p = 0.005). ILD-related hospitalisations were associated with unclassifiable ILD and concomitant emphysema (OR = 2.133, p = 0.001) as well as with other granulomatous ILDs and a positive smoking status (OR = 3.082, p = 0.005). Our results represent a crucial contribution in understanding predisposing factors for hospitalisation in ILD and its major impact on mortality. Further studies to characterize the most vulnerable patient group as well as approaches to prevent hospitalisations are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on hospitalisation patterns in ILD.
METHODS
METHODS
The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for hospitalisations. Reasons for hospitalisation were classified as all cause, ILD-related and respiratory hospitalisations, and patients were analysed for frequency of hospitalisations, time to first non-elective hospitalisation, mortality and progression-free survival. Additionally, the risk for hospitalisation according to GAP index and ILD subtype was calculated by Cox proportional-hazard models as well as influencing factors on prediction of hospitalisation by logistic regression with forward selection.
RESULTS
RESULTS
In total, 601 patients were included. 1210 hospitalisations were recorded during the 6 months prior to registry inclusion until the last study visit. 800 (66.1%) were ILD-related, 59.3% of admissions were registered in the first year after inclusion. Mortality was associated with all cause, ILD-related and respiratory-related hospitalisation. Risk factors for hospitalisation were advanced disease (GAP Index stages II and III) and CTD (connective tissue disease)-ILDs. All cause hospitalisations were associated with pulmonary hypertension (OR 2.53, p = 0.005). ILD-related hospitalisations were associated with unclassifiable ILD and concomitant emphysema (OR = 2.133, p = 0.001) as well as with other granulomatous ILDs and a positive smoking status (OR = 3.082, p = 0.005).
CONCLUSION
CONCLUSIONS
Our results represent a crucial contribution in understanding predisposing factors for hospitalisation in ILD and its major impact on mortality. Further studies to characterize the most vulnerable patient group as well as approaches to prevent hospitalisations are warranted.
Identifiants
pubmed: 38178212
doi: 10.1186/s12931-023-02588-y
pii: 10.1186/s12931-023-02588-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Informations de copyright
© 2023. The Author(s).
Références
Valeyre D, Duchemann B, Annesi-Maesano I, et al. Interstitial lung diseases, in Respiratory Epidemiology, T. Welte, I. Annesi-Maesano, G. Viegi, and B. Lundbäck,Eds., vol. 65 of ERSMonograph, chapter 6, ERS, 2014.
American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.
doi: 10.1164/ajrccm.165.2.ats01
Travis WD, Costabel U, Hansell D. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.
doi: 10.1164/rccm.201308-1483ST
pubmed: 24032382
pmcid: 5803655
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47.
doi: 10.1164/rccm.202202-0399ST
pubmed: 35486072
pmcid: 9851481
Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP, focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–74.
doi: 10.1016/S2213-2600(20)30318-0
pubmed: 32866440
Ma X, Zhu L, Kurche JS, Xiao H, Dai H, Wang C. Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019. Thorax. 2022;77(6):596–605.
doi: 10.1136/thoraxjnl-2020-216732
pubmed: 34556551
Maqhuzu PN, Kreuter M, Bahmer T, Kahn N, Claussen M, Holle R, Schwarzkopf L. Cost drivers in the pharmacological treatment of interstitial lung disease. Respir Res. 2021;22(1):218.
doi: 10.1186/s12931-021-01807-8
pubmed: 34344376
pmcid: 8335870
Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2015;147(1):173–9.
doi: 10.1378/chest.13-2424
pubmed: 25188694
Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res. 2019;20(1):71.
doi: 10.1186/s12931-019-1037-7
pubmed: 30971229
pmcid: 6458653
Hariri LP, Mino-Kenudson M, Mark EJ, et al. Distinct histopathology of acute onset or abrupt exacerbation of hypersensitivity pneumonitis. Hum Pathol. 2012;43(5):660–8.
doi: 10.1016/j.humpath.2011.06.001
pubmed: 21855112
Hozumi H, Nakamura Y, Chida K, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3(9): e003132.
doi: 10.1136/bmjopen-2013-003132
pubmed: 24038004
pmcid: 3773638
Kreuter M, Bendstrup E, Kondoh Y et al., on behalf of the INBUILD trial investigators “Acute exacerbations in patients with progressive fibrosing interstitial lung diseases: data from the INBUILD trial” B94. Learning from registries and clinical trials in ild. Am Thorac Soc, 2022. A3428-A3428.
Kreuter M, Del Galdo F, Miede C, Khanna D, Wuyts WA, Hummers LK, Alves M, Schoof N, Stock C, Allanore Y. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Res Ther. 2022;24(1):19.
doi: 10.1186/s13075-021-02710-9
pubmed: 35012623
pmcid: 8751320
Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, Bénard S. Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS ONE. 2017;12(1): e0166462.
doi: 10.1371/journal.pone.0166462
pubmed: 28099456
pmcid: 5242514
Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020;56(2):1902279.
doi: 10.1183/13993003.02279-2019
pubmed: 32381492
Kreuter M, Herth FJ, Markart P, et al. Exploring clinical and epidemiological characteristics of interstitial lung diseases: rationale, aims, and design of a nationwide prospective registry-the EXCITING-ILD registry. Biomed Res Int. 2015;2015: 123876.
doi: 10.1155/2015/123876
pubmed: 26640781
pmcid: 4657073
Ryerson CJ, Vittinghoff E, Collard HR, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–8.
doi: 10.1378/chest.13-1474
pubmed: 24114524
Wälscher J, Witt S, Schwarzkopf L, Kreuter M. Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment—a German claims data analysis. Respir Res. 2020;21(1):73.
doi: 10.1186/s12931-020-01335-x
pubmed: 32216792
pmcid: 7098099
Lassenius MI, Toppila I, Pöntynen N, Kasslin L, Kaunisto J, Kilpeläinen M, Laitinen T. Forced vital capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. Eur Clin Respir J. 2019;7(1):1702618.
doi: 10.1080/20018525.2019.1702618
pubmed: 32002175
pmcid: 6968594
Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet Investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.
doi: 10.1186/1465-9921-14-73
pubmed: 23848435
pmcid: 3729659
Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–63.
doi: 10.1183/09031936.00159709
pubmed: 20595144
Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun. 2011;37(4):273–88.
doi: 10.1016/j.jaut.2011.08.002
pubmed: 21907543
Xing NS, Fan GZ, Yan F, Liu YP, Zhang R. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Int Immunopharmacol. 2021;95: 107524.
doi: 10.1016/j.intimp.2021.107524
pubmed: 33721757
Marijic P, Schwarzkopf L, Maier W, Trudzinski F, Schwettmann L, Kreuter M. Effects of influenza vaccination in patients with interstitial lung diseases: an epidemiological claims data analysis. Ann Am Thorac Soc. 2022;19(9):1479–88.
doi: 10.1513/AnnalsATS.202112-1359OC
pubmed: 35312465
pmcid: 9447394